Do You the Latest on Tardive Dyskinesia?
A quiz based on the latest tardive dyskinesia news and studies.
Read More
Author: Rebecca Shover
AI and ML Show Promise in Targeting Therapies for Chronic Lymphocytic Leukemia
AI and ML advances chronic lymphocytic leukemia therapies.
Read More
Medical Fiction: Cookies, Cutlery, and a Kitchen Crime
In this medical fiction, Hildi’s misfit cookies spark a unique friendship with chef Mindy, and dramatic kitchen confrontations build a bond beyond baking.
Read More
Nivolumab Ipilimumab Combination Outperforms Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma
Patients with unresectable hepatocellular carcinoma reported better results with nivolumab ipilimumab.
Read More
Immune-Enhancing Nutrition has no Effect on Complication Rates After Radical Cystectomy
Patients with a radical cystectomy did not have fewer complications with an immune-enhancing nutrition drink
Read More
Baseline Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer has Both Prognostic & Predictive Value
An analysis of the PSMAfore trial suggests that baseline circulating tumor DNA could have predictive and prognostic value for patients.
Read More
Osimertinib Significantly Improves Progression-Free Survival for Patients With Unresectable Stage III & EGFR-Mutated NSCLC
Patients with non-small cell lung cancer have shown improvements with chemoradiotherapy in a new study.
Read More
Neoadjuvant Intralesional Daromun Improves Relapse Free Survival in Stage III Melanoma
The phase 3 PIVOTAL study has shown that neoadjuvant intralesional daromun can benefit patients with pretreated stage III melanoma.
Read More
A Curated COPD eBook
A curated ebook on chronic obstructive pulmonary disease (COPD featuring recent studies, findings, and opinions from thought leaders.
Read More
Adjuvant Avelumab Significantly Improves Survival in Early Triple-Negative Breast Cancer
A study finds 1 year of avelumab treatment improves distant disease free and overall survival rates in patients with early triple-negative breast cancer.
Read More
Benefit of Nivolumab/Ipilimumab in MSI-H/dMMR Metastatic Colorectal Cancer Maintenance Beyond First Line
An analysis of the benefits of nivolumab/ipilimumab in MSI-H/dMMR metastatic colorectal cancer on progression free survival rate.
Read More
Equivalent Benefit of Video Delivered & in Person Delivered Palliative Care
Virtual or in person palliative care has shown significant results for patients with non-small cell lung cancer that is incurable.
Read More
Perioperative Chemotherapy Outperforms Neoadjuvant Chemoradiation in Resectable Oesophageal Cancer
Patients with resectable oesophageal cancer have better results with perioperative chemotherapy and surgery than neoadjuvant chemoradiation and surgery.
Read More
Metformin Does Not Prevent Progression of Low Risk Prostate Cancer
Metformin, has been found to not benefit patients with low risk prostate cancer.
Read More
Batiraxcept-Paclitaxel Combination Shows Promise in High AXL-Expressing, Platinum-Resistant Ovarian Cancer
Batiraxcept and paclitaxel as a combination therapy has shown significant results in improving progression free survival and overall rates.
Read More
Crohn’s & Colitis eBook
A curated ebook on Crohn’s and colitis featuring recent studies, findings, and opinions from thought leaders.
Read More
Highly Significant Event Free Survival Benefit With Neoadjuvant Ipilimumab/Nivolumab in Stage 3 Melanoma
Patients with macroscopic stage 3 melanoma have seen improvements with neoadjuvant ipilimumab/nivolumab intake.
Read More
No Survival Benefit of Tumor Debulking for Patients With Multiorgan Metastatic Colorectal Cancer
A phase 3 trial has found that there is no survival benefit for tumor debulking in addition to palliative combination chemotherapy.
Read More
Adding Abemaciclib to Fulvestrant Improves Progression-Free Survival in Advanced HR+/HER2-Negative Breast Cancer After Progression on CDK4/6 Inhibitor and Endocrine Therapy
Abemaciclib in combination with fulvestrant can benefit progression free survival rates in patients with HR+/HER2-negative breast cancer.
Read More